Allergy And Immunology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), Tablets, Drops), By Allergy Type (Allergic Rhinitis, Allergic Asthma, Other Allergies), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 2.81 Billion
CAGR (2026-2031)	5.88%
Fastest Growing Segment	Hospital Pharmacy
Largest Market	North America
Market Size (2031)	USD 3.96 Billion

Market Overview

The Global Allergy And Immunology Market will grow from USD 2.81 Billion in 2025 to USD 3.96 Billion by 2031 at a 5.88% CAGR. The Global Allergy and Immunology Market encompasses diagnostic tests, immunotherapies, and pharmaceutical treatments designed to identify and manage immune system disorders such as asthma, autoimmune diseases, and hypersensitivities. The market is primarily driven by the escalating global prevalence of allergic conditions resulting from environmental pollution and urbanization which necessitates consistent demand for chronic management solutions. Furthermore, increasing healthcare expenditures and greater awareness of immune diseases support the sustained expansion of this sector distinct from temporary technological shifts.

However, the substantial cost associated with developing and administering advanced biologic therapies poses a significant challenge that could impede market accessibility in developing regions. This economic burden is critical given the immense patient population requiring care and the need for scalable solutions. According to the Asthma and Allergy Foundation of America, in 2024, allergic conditions affected over 100 million people in the United States, illustrating the profound scale of the addressable market and the urgent necessity for economically viable therapeutic innovations.

Key Market Drivers

The Rising Global Incidence of Allergic and Autoimmune Disorders acts as a fundamental catalyst for market growth, necessitating a shift from episodic treatment to long-term disease management. Environmental stressors, including rapid urbanization and changing dietary patterns, have contributed to a heightened sensitivity among populations worldwide, expanding the addressable patient pool for diagnostic and therapeutic solutions. This trend is not limited to westernized nations but is becoming a global health concern requiring consistent medical intervention. According to Frontiers in Nutrition, June 2024, in the 'Food allergies around the world' article, globally defined statistics estimate that food allergies now affect approximately 8% of children and 10% of adults. Consequently, healthcare systems are prioritizing accurate diagnostics and sustained therapeutic interventions, fueling a consistent demand for allergy care products and services.

Concurrently, the Acceleration of Biologic and Immunotherapy Drug Innovations is transforming the sector by introducing targeted therapies that address the root causes of immune dysregulation rather than merely suppressing symptoms. Pharmaceutical developers are increasingly investing in monoclonal antibodies and desensitization therapies that offer higher efficacy for severe and complex conditions. A pivotal advancement occurred when, according to Genentech, February 2024, in the 'FDA Approves Xolair' press release, the U.S. FDA approved Xolair as the first and only medicine to reduce allergic reactions in patients with one or more food allergies. The commercial scale of such advanced treatments is immense and indicates strong market viability; according to AbbVie, in October 2024, global net revenues from its immunology portfolio reached $7.05 billion in the third quarter alone, underscoring the substantial economic value generated by next-generation immunology solutions.

Download Free Sample Report

Key Market Challenges

The substantial cost associated with developing and administering advanced biologic therapies poses a significant barrier to the growth of the Global Allergy and Immunology Market. These complex treatments require extensive research and development investment, resulting in high pricing that limits their accessibility. Consequently, healthcare systems in developing regions and patients with limited insurance coverage often cannot afford these necessary medications. This financial exclusivity restricts the market from capitalizing on the rising prevalence of allergic conditions, as a large portion of the addressable patient population remains unable to access these advanced therapeutic options.

The economic burden of allergic diseases is already immense, creating resistance to adopting further expensive interventions. According to the Asthma and Allergy Foundation of America, in 2024, the annual economic cost of asthma to the United States economy exceeded $82 billion. This figure highlights the financial strain on healthcare infrastructures, making payers less likely to approve or subsidize high priced biologic therapies. As a result, the market experiences constrained expansion, as fiscal limitations impede the widespread adoption of effective but expensive immunological treatments.

Key Market Trends

The market is witnessing a distinct transition toward Sublingual Immunotherapy (SLIT) as a preferred alternative to traditional subcutaneous injections, driven by the demand for non-invasive and convenient home-based treatments. This modality improves patient adherence by eliminating the need for frequent clinic visits associated with allergy shots, making it particularly attractive for pediatric and working-age populations who require long-term desensitization. Pharmaceutical companies are capitalizing on this shift by expanding portfolios of standardized allergy tablets that target common triggers like grass pollen and house dust mites. Validating this commercial momentum, according to ALK-Abelló, February 2025, in the 'Annual Report 2024', global sales of its allergy immunotherapy tablets increased by 24% compared to the previous year, highlighting the rapid uptake of oral formulations over injectable counterparts.

Concurrently, the adoption of telehealth platforms is reshaping care delivery by enabling remote symptom monitoring and virtual consultations for chronic allergy management. This digital integration addresses the scarcity of specialists in rural areas and facilitates hybrid care models where initial assessments are conducted online, streamlining patient flow and reducing wait times. The integration of digital tools allows allergists to track patient responses to desensitization therapies in real-time, thereby optimizing treatment protocols without requiring physical presence. Highlighting this behavioral shift, according to the National Institutes of Health, November 2025, in the 'TeleAllergy: Potential of Telemedicine in Management of Patients With Allergies' report, a survey of allergic patients revealed that 34% had specifically utilized telemedicine services to manage their allergic conditions, underscoring the growing reliance on virtual care channels.

Segmental Insights

The Hospital Pharmacy segment represents the fastest-growing division within the Global Allergy and Immunology Market due to the rising incidence of severe allergic conditions requiring hospitalization. This accelerated growth is primarily driven by the increasing administration of complex treatments and biologics that mandate professional medical supervision during dispensing. Furthermore, the growing prevalence of immune deficiency disorders necessitates distinct inpatient care and specialized medication management available exclusively in hospital settings. Consequently, the reliance on clinical environments for administering high-risk immunological therapies solidifies the position of hospital pharmacies as a rapidly expanding distribution channel.

Regional Insights

North America maintains a leading position in the Global Allergy and Immunology Market, driven by a well-developed healthcare infrastructure and significant investment in clinical research. The region benefits from a dense concentration of major pharmaceutical companies that accelerate the development of innovative therapies. The U.S. Food and Drug Administration supports this ecosystem through clear regulatory frameworks, streamlining the approval of new biologics and immunotherapies. Furthermore, comprehensive reimbursement policies ensure widespread patient access to specialized care. This favorable commercial environment, combined with a rising prevalence of allergic conditions, secures the region’s dominance in the global landscape.

Recent Developments

• In September 2025, Regeneron Pharmaceuticals reported positive results from two Phase 3 trials evaluating its novel investigational allergen-blocking antibodies for the treatment of cat and birch pollen allergies. The studies met their primary endpoints, demonstrating that the new therapies significantly reduced allergic symptoms, such as nasal and ocular irritation, following a single dose. These antibodies were developed using the company's proprietary VelocImmune technology and represent a potential breakthrough in allergy management by offering rapid and durable relief. The company indicated that these findings would support future regulatory submissions, positioning the candidates as a new class of biologics for patients suffering from severe environmental allergies.
• In October 2024, GSK announced a new five-year collaboration with the University of Cambridge and Cambridge University Hospitals, supported by a £50 million investment, to accelerate the development of treatments for immune-related respiratory and kidney diseases. The partnership, known as the Cambridge-GSK Translational Immunology Collaboration, aims to utilize artificial intelligence and machine learning to integrate patient data and gain deeper insights into human immune biology. By focusing on the mechanisms of disease progression and patient responses, the initiative seeks to identify new therapeutic targets and biomarkers, ultimately streamlining the discovery of precision medicines for complex immunological disorders.
• In April 2024, Vertex Pharmaceuticals entered into a definitive agreement to acquire Alpine Immune Sciences for approximately $4.9 billion in cash, a strategic move designed to significantly expand its portfolio in the Global Allergy and Immunology Market. This acquisition provided Vertex with access to Alpine’s lead molecule, povetacicept, a highly potent dual antagonist of BAFF and APRIL cytokines, which is being developed for the treatment of IgA nephropathy and other serious autoimmune diseases. The transaction underscored the growing industry focus on developing protein-based immunotherapies to address kidney diseases and other inflammatory conditions with high unmet medical needs.
• In February 2024, the U.S. Food and Drug Administration granted approval to Genentech, a member of the Roche Group, for Xolair (omalizumab) to reduce allergic reactions, including anaphylaxis, in adults and children aged one year and older with immunoglobulin E-mediated food allergies. This regulatory milestone established the therapy as the first and only medicine approved to reduce allergic reactions to multiple foods following accidental exposure. The approval was supported by data from a National Institutes of Health-sponsored Phase 3 study, which demonstrated that a significantly higher proportion of treatment recipients could tolerate specific amounts of peanut, milk, egg, and cashew without experiencing moderate to severe symptoms compared to the placebo group.

Key Market Players

• AbbVie Inc.
• Stallergenes Greer PLC
• Allergy Therapeutics
• Sanofi SA
• Anacor Pharmaceuticals Inc.
• Novartis International AG
• AstraZeneca
• Merck KGaA
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson
• GlaxoSmithKline PLC
• Mylan N.V.

By Treatment Type	By Allergy Type	By Distribution Channel	By Region
Subcutaneous Immunotherapy (SCIT) Sublingual Immunotherapy (SLIT) Tablets Drops	Allergic Rhinitis Allergic Asthma Other Allergies	Hospital Pharmacy Retail Pharmacy Online Pharmacy	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Allergy And Immunology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Allergy And Immunology Market, By Treatment Type:

• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)
• Tablets
• Drops

• Allergy And Immunology Market, By Allergy Type:

• Allergic Rhinitis
• Allergic Asthma
• Other Allergies

• Allergy And Immunology Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

• Allergy And Immunology Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE